Warren Street Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$248K Buy
555
+52
+10% +$24.2K 0.06% 104
2025
Q4
$228K Sell
503
-56
-10% -$24.1K 0.07% 101
2025
Q3
$219K Sell
559
-50
-8% -$20.9K 0.07% 136
2025
Q2
$271K Buy
609
+100
+20% +$46.1K 0.09% 100
2025
Q1
$247K Buy
+509
New +$237K 0.1% 92

Other funds holding VRTX

Warren Street Wealth Advisors's VRTX Position: Q1 2026 in Review

Warren Street Wealth Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 10% in Q1 2026, buying an estimated $24.2K and bringing the position to 555 shares worth $248K. The position accounts for 0.06% of the portfolio, ranked #104.

Warren Street Wealth Advisors first reported a position in VRTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $271K in Q2 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Warren Street Wealth Advisors held 555 shares of Vertex Pharmaceuticals worth $248K as of Q1 2026.
  • Warren Street Wealth Advisors bought 52 Vertex Pharmaceuticals shares in Q1 2026, an estimated $24.2K.
  • Vertex Pharmaceuticals made up 0.06% of Warren Street Wealth Advisors's portfolio in Q1 2026, its #104 holding.
  • Warren Street Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Warren Street Wealth Advisors's Vertex Pharmaceuticals position peaked at $271K in Q2 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Warren Street Wealth Advisors's 13F filing for Q1 2026, filed 16 Apr 2026.